ZYUS Life Sciences Awarded EU-GMP Certification, Enables Expansion into Rapidly Growing Global Medical Cannabinoids Markets

ZYUS Life Sciences Awarded EU-GMP Certification, Enables Expansion into Rapidly Growing Global Medical Cannabinoids Markets
CANNANNEW REPORT

GMP certification is a key growth catalyst and element of global supply chain and distribution strategy SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that the company’s Canadian manufacturing facility has been awarded EU-Good Manufacturing Practice (“EU-GMP”) certification. Receipt of this certification is an essential requirement for the export of cannabinoid oil formulations into the European Union (EU). This also independently verifies that ZYUS’ manufacturing processes have been developed to produce clinical trial drug product candidates and commercial products meeting rigorous EU-GMP standards. EU-GMP certification, an internationally recognized certification granted only to companies whose manufacturing procedures and facilities demonstrate a high degree of consistency, precision, and quality in all stages of production, provides ZYUS the opportunity to pursue international distribution opportunities in the EU, as well as in other global markets that accept EU-GMP certification for market access, such as certain countries located in Latin America and Oceania. ZYUS’ EU-GMP certification was granted by Portugal’s Infarmed — National Authority of Medicines and Health Products, I.P. — that evaluates, authorizes, and regulates medicines and medical devices for the protection of public health. Infarmed pursues its activity in several domains at national and European levels, and during its extensive audit of ZYUS’ industry leading, pharmaceutical-grade cannabinoid extraction facility, ZYUS demonstrated that its leading-edge Canadian site together with its manufacturing facilities and extensive processes and documentation consistently met or exceeded the stringent EU-GMP certification requirements as a medicines manufacturer. “At ZYUS, we are committed to providing patients in Canada and worldwide with high quality cannabinoid-based formulations backed by our team’s decades-long leadership in medical cannabinoids,” said ZYUS CEO Brent Zettl. “By achieving EU-GMP certification, we can now begin to execute upon our well-developed plans for expansion into a number of…

Excerpt only …
READ MORE BELOW
Source : ZYUS Life Sciences Awarded EU-GMP Certification, Enables Expansion into Rapidly Growing Global Medical Cannabinoids Markets

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.